Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial ; volume:3 ; number:2 ; day:19 ; month:4 ; year:2011 ; pages:1-11 ; date:4.2011
Alzheimer's research & therapy ; 3, Heft 2 (19.4.2011), 1-11, 4.2011
- Creator
-
Piette, François
- Contributor
-
Belmin, Joël
Vincent, Hélène
Schmidt, Nicolas
Pariel, Sylvie
Verny, Marc
Marquis, Caroline
Mely, Jean
Hugonot-Diener, Laurence
Kinet, Jean-Pierre
Dubreuil, Patrice
Moussy, Alain
Hermine, Olivier
SpringerLink (Online service)
- DOI
-
10.1186/alzrt75
- URN
-
urn:nbn:de:1111-2016073131260
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Piette, François
- Belmin, Joël
- Vincent, Hélène
- Schmidt, Nicolas
- Pariel, Sylvie
- Verny, Marc
- Marquis, Caroline
- Mely, Jean
- Hugonot-Diener, Laurence
- Kinet, Jean-Pierre
- Dubreuil, Patrice
- Moussy, Alain
- Hermine, Olivier
- SpringerLink (Online service)
Other Objects (12)
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Adjunct therapy with probiotics for chronic urticaria in children: randomised placebo-controlled trial
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial
Zinc adjunct therapy reduces case fatality in severe childhood pneumonia: a randomized double blind placebo-controlled trial
Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial
Moderate to severe HIV-associated neurocognitive impairment : A randomized placebo-controlled trial of lithium
Adjunct prednisone in community-acquired pneumonia: 180-day outcome of a multicentre, double-blind, randomized, placebo-controlled trial
Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
Aesthetic Correction of Mild-to-Moderate Blepharoptosis Among Asians: The Bridge Technique
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Adjunct therapy with probiotics for chronic urticaria in children: randomised placebo-controlled trial
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial
Zinc adjunct therapy reduces case fatality in severe childhood pneumonia: a randomized double blind placebo-controlled trial
Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial
Moderate to severe HIV-associated neurocognitive impairment : A randomized placebo-controlled trial of lithium
Adjunct prednisone in community-acquired pneumonia: 180-day outcome of a multicentre, double-blind, randomized, placebo-controlled trial
Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
Aesthetic Correction of Mild-to-Moderate Blepharoptosis Among Asians: The Bridge Technique
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Adjunct therapy with probiotics for chronic urticaria in children: randomised placebo-controlled trial
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial
Zinc adjunct therapy reduces case fatality in severe childhood pneumonia: a randomized double blind placebo-controlled trial
Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial
Moderate to severe HIV-associated neurocognitive impairment : A randomized placebo-controlled trial of lithium
Adjunct prednisone in community-acquired pneumonia: 180-day outcome of a multicentre, double-blind, randomized, placebo-controlled trial
Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial